PDCD1LG2 and breast cancer: Based on the IC50 values (see Table 1), it can be observed that the lipid-encapsulated Pd(II) complexes (IC50 1.93 ± 0.29 μg/mL for PdL1LNPs and 2.03 ± 0.21 μg/mL for PdL2LNPs) exhibited enhanced cytotoxicity in comparison to their non-encapsulated counterparts (IC50 16.28 ± 0.56 μg/mL for PdL1 and 23.72 ± 1.25 μg/mL for PdL2) when targeting breast cancer cells (MCF-7).